newsfilter
← Earnings
Earnings Releases·

Shattuck Labs — Third Quarter 2026 Earnings Summary

  • Cash and short-term investments increased to $196.3 million as of September 30, 2026, from $86.1 million in the prior year period, while R&D expenses rose to $21.6 million from $7.6 million; net loss widened to $25.2 million ($0.14 per share) from $10.1 million in the same quarter last year.
  • The company initiated the RECEPTIVE-CD1 Phase 2b trial for SL-325 in Crohn's disease and plans to start the RECEPTIVE-HS1 Phase 2 trial for hidradenitis suppurativa in Q4 2026, with 12-week induction and primary treatment data expected in H1 2028.
  • Initial Phase 1 clinical data for the SL-846 candidate is projected for 2027, following preclinical results indicating a superior immunogenicity profile with a projected human anti-drug antibody rate of 8-12%.
  • Current cash resources are sufficient to fund operations through 2029, and the company submitted an IND application for SL-325 in October 2026.
Company
SHATTUCK LABS INC
Sector
Healthcare
Industry
Biotechnology